Journal: Science Advances

Article Title: Biofunctional lipid nanoparticles for precision treatment and prophylaxis of bacterial infections

doi: 10.1126/sciadv.adk9754

Figure Lengend Snippet: ( A ) Expression levels of CD80 + and CD86 + in BMDCs (CD11c + ) and ( B ) production of IL-6 and TNF-α of the cell supernatant measured by ELISA after different treatments (concentration, 2 μg ml −1 NPs) for 24 hours ( n = 3). ( C ) Schematics of experimental design to evaluate the in vivo short-term immune responses activated by a single dose of various LNPs (20 μg/20 g) via subcutaneous injection. ( D ) Percentage of CD80 + and ( E ) CD86 + cells (gated on CD11c + cells) in the LNs at day 3 after immunization ( n = 6). ( F ) Percentage of CD3 + T cells, ( G ) CD8 + T cells (gated on CD3 + T cells), and ( H ) CD4 + T cells (gated on CD3 + T cells) in the spleen at day 3 after immunization ( n = 6). Naive mice without immunization were used as control. * P < 0.05, ** P < 0.01, and *** P < 0.001.

Article Snippet: Fluorescein isothiocyanate (FITC)–conjugated anti-mouse CD11c, phycoerythrin (PE)–conjugated anti-mouse CD80, PE-conjugated anti-mouse CD86, allophycocyanin (APC)–conjugated anti-mouse CD3, PE-conjugated anti-mouse CD8a, and FITC-conjugated anti-mouse CD4 were purchased from Tonbo Biosciences, USA.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay, In Vivo, Injection, Control

Journal: Materials Today Bio

Article Title: A MnO 2 -based tumor-seeking nanoplatform for enhanced chemoimmunotherapy against 4T1 breast cancer

doi: 10.1016/j.mtbio.2025.102000

Figure Lengend Snippet: In vitro BMDC Maturity and BMDM Repolarization Assay. Representative flow cytometry graph of CD80 + CD86 + cells in BMDCs after treated with normal saline (A), PTX injections (B), Squ@APS-IR820 NPs (C), MnO 2 @APS-IR820 NPs (D), Squ@APS NPs + MnO 2 @APS NPs (E), and Squ@APS-IR820 NPs + MnO 2 @APS-IR820 NPs (F). Percentages of CD80 + CD86 + cells (G). Flow cytometry chart of CD86 + CD206 - cells (H–M) and quantification of the proportion (N) of CD86 + CD206 - BMDMs after being incubated with different treatments (n = 3). Differences among groups were calculated by one-way ANOVA analysis. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. ns, no significance.

Article Snippet: Antibody: Anti-mouse CD16/32 Antibody was provided by Elabscience Biotechnology Co., Ltd, Anti-mouse CD11c PE, anti-mouse CD80 FITC, anti-mouse CD86 APC, anti-mouse CD86-PE, anti-mouse CD45-APC was purchased from Proteintech Group, Inc (Hubei, China).

Techniques: In Vitro, Flow Cytometry, Saline, Incubation

Journal: Materials Today Bio

Article Title: A MnO 2 -based tumor-seeking nanoplatform for enhanced chemoimmunotherapy against 4T1 breast cancer

doi: 10.1016/j.mtbio.2025.102000

Figure Lengend Snippet: Immunoassay of the tumor and the spleen after different treatments. (A) Workflow of the immunoassay based on Flow Cytometry. Created in BioRender. Gong, T. (2025) https://BioRender.com/tjhnwh2 . Representative flow cytometry plots of tumor immune cells including CD3 + CD8 + T cells (B), CD11b + Ly6c + MDSCs (C). Representative flow cytometry plots of splenic immune cells including CD80 + CD86 + DCs (D), CD3 + CD8 + T cells (E), and CD3 - B220 + B cells (F). The quantitative analysis of CD3 + CD8 + T cells (G), CD11b + Ly6c + MDSCs (H) in the tumor and CD80 + CD86 + DCs (I), CD3 + CD8 + T cells (J), and CD3 - B220 + B cells (K) in the spleen after different treatments. Data are presented as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001. ns, no significant difference between two groups.

Article Snippet: Antibody: Anti-mouse CD16/32 Antibody was provided by Elabscience Biotechnology Co., Ltd, Anti-mouse CD11c PE, anti-mouse CD80 FITC, anti-mouse CD86 APC, anti-mouse CD86-PE, anti-mouse CD45-APC was purchased from Proteintech Group, Inc (Hubei, China).

Techniques: Flow Cytometry

Journal: Journal of Cellular and Molecular Medicine

Article Title: TREM2 expression promotes liver and peritoneal M2 macrophage polarization in mice infected with Schistosoma japonicum

doi: 10.1111/jcmm.17842

Figure Lengend Snippet: Trem2 deletion increases F4/80 + CD86+ cells in peritoneal macrophages. (A) TREM2 expression is upregulated in peritoneal macrophages from mice infected with Schistosoma japonicum . The number of TREM2+ cells in F4/80 + CD11b + peritoneal macrophages was determined by flow cytometry and compared to uninfected controls. * p < 0.05, ** p < 0.01, *** p < 0.001. (B) The number of F4/80 + CD86+ cells in total peritoneal macrophages obtained from wild‐type or Trem2 −/− mice with or without IL4/13 stimulation was determined by flow cytometry. ** p < 0.01. (C) The number of F4/80 + CD206+ cells in total peritoneal macrophages obtained from wild‐type or Trem2 −/− mice with or without IL4/13 stimulation was determined by flow cytometry. * p < 0.05. All results are relative to their respective controls.

Article Snippet: For this, the cells were incubated with PE conjugated antibody against mouse F4/80 (02922–60, Biogems), PE‐Cy7 conjugated antibody against mouse CD11b (03221–77, Biogems), APC conjugated antibody against mouse CD86 or CD206 (17–0862, 17–2061, eBioscience) and FITC conjugated antibody against mouse TREM2 (ab119852, Abcam).

Techniques: Expressing, Infection, Flow Cytometry